Suchergebnisse

Background and Objectives: Breast milk contains several bioactive factors including oligosaccharides (HMO) and microbes that shape the infant gut microbiota. HMO profile is determined by secretor status, however their influence on milk microbiota is still uncovered. This study is aimed to determine the impact of the FUT2 genotype on the milk microbiota during the first month of lactation and the association with HMO. Methods: Milk microbiota from 25 healthy lactating women was determined by quantitative PCR and 16S gene pyrosequencing. Secretor genotype was obtained by PCR-RFLPs and by HMO identification and quantification. Results: The most abundant bacteria were Staphylococcus and Streptococcus, followed by enterobacteriaceae-related bacteria. The predominant HMO in secretor milk samples were 2FL and LNFP I whereas non-secretor milk was characterized by LNFP II and LNDFH II. Differences in microbiota composition and quantity were found depending on secretor/non-secretor status. Lactobacillus spp, Enterococcus spp., and Streptococcus spp. were lower in non-secretor than in secretor samples. Bifidobacterium genus and species were less prevalent in non-secretor samples. Despite no differences on diversity and richness, non-secretor samples had lower Actinobacteria and higher relative abundance of Enterobacteriaceae, Lactobacillaceae and Staphylococcaceae. Conclusions: Maternal secretor status is associated with the human milk microbiota composition and is maintained during the first 4 weeks. Specific associations between milk microbiota, HMO and secretor status were observed although the potential biological impact on the neonate remains elusive. Future studies are needed to reveal the early nutrition influence on the reduction of risk of disease. ; European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (ERC Starting Grant, 639226). ; Peer reviewed

The new guidelines of the European Commission on infant and follow-on formulae stipulate that from February 2020 onwards all such products sold in the European Union must contain a high amount of 20–50 mg/100 kcal of the omega 3-fatty acid docosahexaenoic acid (DHA, ≈0.5–1% of fatty acids), while there is no requirement to include arachidonic acid (ARA, omega 6-fatty acids). This novel compositional concept for infant formulae has raised controversy and concerns because there is no accountable evidence for its suitability and safety. In accordance with the European Academy of Paediatrics, the Committee on Nutrition of the German Society for Pediatrics and Adolescent Medicine recommends the use of infant and follow-on formulae that contain at least the same amount of ARA along with DHA, as long as no convincing data on the suitability and safety of alternative concepts are available based on adequately designed and powered clinical trials.